Skip to main content
TRAW
NASDAQ Life Sciences

Traws Pharma Launches Antiviral Program for Hantavirus and Ebola Outbreaks

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.64
Mkt Cap
$23.938M
52W Low
$0.995
52W High
$3.265
52W Position info
65% above low
Off High info
50% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

TRAW sits 65% above its 52-week low of $0.995 on light trading volume (0.3× avg).

Summary

Traws Pharma announced a new antiviral program for Hantavirus and Ebola, aiming for fast-track development and manufacturing scale-up, a significant strategic move for the financially distressed biotech.


Key Events · Product Development and Regulatory · TRAW

  • New Antiviral Program Announced

    Traws Pharma is advancing a novel proprietary broad-spectrum combination anti-viral agent targeting ongoing Hantavirus and Ebola Virus disease outbreaks.

  • Novel Dual-Strike Mechanism

    The investigational combination utilizes a unique 'dual-strike' mechanism of action that hijacks host cell pathways to force viral eradication, maximizing potency while minimizing toxicity.

  • Fast-Track Development & Global Access

    The company plans interactions with the US CDC, Nigerian NAFDAC, and African Medicines Agency (AMA) to fast-track clinical development, emergency manufacturing scale-up, and ensure global access.

  • Leadership Credibility

    Robert R. Redfield, MD, Chief Medical Officer of Traws Pharma and former Head of the CDC, emphasized the program's potential and cooperation with health agencies.


Analysis · TRAW · Life Sciences

Traws Pharma, a clinical-stage biopharmaceutical company facing a 'going concern' warning and zero revenue, announced a new antiviral program targeting ongoing Hantavirus and Ebola outbreaks. This strategic move, featuring a novel 'dual-strike' mechanism and led by a former CDC head, aims for fast-track clinical development and emergency manufacturing. This initiative could be a critical lifeline, potentially attracting significant funding or partnerships and addressing the company's dire financial situation by opening a new, high-impact revenue stream.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TRAW was trading at $1.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.9M. The 52-week trading range was $1.00 to $3.27. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TRAW - Latest Insights

TRAW
Nov 12, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.252
Real-time Price: $0.2425 info
Change: -$0.0095 (-4%) info
Market Cap: $3.727M info
TRAW
Oct 26, 2026, 4:47 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $0.350
Real-time Price: $0.2425 info
Change: -$0.1075 (-31%) info
Market Cap: $3.727M info
TRAW
Oct 23, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3425
Real-time Price: $0.2425 info
Change: -$0.100 (-29%) info
Market Cap: $3.727M info
TRAW
Oct 20, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.3767
Real-time Price: $0.2425 info
Change: -$0.1342 (-36%) info
Market Cap: $3.727M info
TRAW
Oct 08, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.4803
Real-time Price: $0.2425 info
Change: -$0.2378 (-50%) info
Market Cap: $3.727M info